{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T12:27:20Z","timestamp":1787660840575,"version":"build-2736575974"},"reference-count":53,"publisher":"Society of Nuclear Medicine","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2026,4,16]]},"published-print":{"date-parts":[[2026,8]]},"DOI":"10.2967\/jnumed.125.271469","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T14:50:13Z","timestamp":1779375013000},"page":"1268-1275","source":"Crossref","is-referenced-by-count":0,"title":["Assessing Value for Money in Theranostic Nuclear Medicine: A Systematic Review"],"prefix":"10.2967","volume":"67","author":[{"given":"Yufan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristofer J.","family":"Thurecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Yu","family":"Yeoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitham","family":"Tuffaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"2026082505102227000_67.8.1268.1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.semradonc.2020.07.009","article-title":"Radiopharmaceutical delivery for theranostics: pharmacokinetics and pharmacodynamics","volume":"31","author":"Sunderland","year":"2021","journal-title":"Semin Radiat Oncol."},{"key":"2026082505102227000_67.8.1268.2","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1016\/S1470-2045(24)00145-1","article-title":"Translating the theranostic concept to neuro-oncology: disrupting barriers","volume":"25","author":"Albert","year":"2024","journal-title":"Lancet Oncol."},{"key":"2026082505102227000_67.8.1268.3","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00652-y"},{"key":"2026082505102227000_67.8.1268.4","doi-asserted-by":"crossref","first-page":"102940","DOI":"10.1016\/j.ctrv.2025.102940","article-title":"Radioligand therapy in metastatic breast cancer: harnessing precision oncology","volume":"136","author":"Giugliano","year":"2025","journal-title":"Cancer Treat Rev."},{"key":"2026082505102227000_67.8.1268.5","doi-asserted-by":"crossref","first-page":"e250","DOI":"10.1016\/S1470-2045(24)00037-8","article-title":"Trends in nuclear medicine and the radiopharmaceutical sciences in oncology: workforce challenges and training in the age of theranostics","volume":"25","author":"Scott","year":"2024","journal-title":"Lancet Oncol."},{"key":"2026082505102227000_67.8.1268.6","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/S1470-2045(24)00482-0","article-title":"Spillover benefits of workforce capacity building in radiotherapy","volume":"25","author":"Ngwa","year":"2024","journal-title":"Lancet Oncol."},{"key":"2026082505102227000_67.8.1268.7","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1016\/S1470-2045(24)00041-X","article-title":"Production and regulatory issues for theranostics","volume":"25","author":"Giammarile","year":"2024","journal-title":"Lancet Oncol."},{"key":"2026082505102227000_67.8.1268.8","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1016\/S1470-2045(24)00407-8","article-title":"Radiotherapy and theranostics: a Lancet Oncology Commission","volume":"25","author":"Abdel-Wahab","year":"2024","journal-title":"Lancet Oncol."},{"key":"2026082505102227000_67.8.1268.9","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1017\/S1744133123000038","article-title":"We need to talk about values: a proposed framework for the articulation of normative reasoning in health technology assessment","volume":"19","author":"Charlton","year":"2024","journal-title":"Health Econ Policy Law."},{"key":"2026082505102227000_67.8.1268.10","doi-asserted-by":"crossref","first-page":"107491","DOI":"10.1016\/j.ypmed.2023.107491","article-title":"Economic evaluation of exercise interventions for individuals with cancer: a systematic review","volume":"172","author":"Wang","year":"2023","journal-title":"Prev Med."},{"key":"2026082505102227000_67.8.1268.11","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40273-024-01446-z","article-title":"Unravelling the association between uncertainties in model-based economic analysis and funding recommendations of medicines in Australia","volume":"43","author":"Chen","year":"2025","journal-title":"Pharmacoeconomics."},{"key":"2026082505102227000_67.8.1268.12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"2026082505102227000_67.8.1268.13","doi-asserted-by":"publisher","DOI":"10.1332\/174426410X482999"},{"key":"2026082505102227000_67.8.1268.14","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.jval.2023.04.004","article-title":"Developing criteria for health economic quality evaluation tool","volume":"26","author":"Kim","year":"2023","journal-title":"Value Health."},{"key":"2026082505102227000_67.8.1268.15","doi-asserted-by":"crossref","first-page":"23814683211061097","DOI":"10.1177\/23814683211061097","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"7","author":"Husereau","year":"2022","journal-title":"MDM Policy Pract."},{"key":"2026082505102227000_67.8.1268.16","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s12913-022-07595-1","article-title":"Meta-analysis of economic evaluation studies: data harmonisation and methodological issues","volume":"22","author":"Bagepally","year":"2022","journal-title":"BMC Health Serv Res."},{"key":"2026082505102227000_67.8.1268.17","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.euf.2020.02.010","article-title":"Cost-effectiveness analysis of 99mTc-sestamibi SPECT\/CT to guide management of small renal masses","volume":"7","author":"Su","year":"2021","journal-title":"Eur Urol Focus."},{"key":"2026082505102227000_67.8.1268.18","doi-asserted-by":"crossref","first-page":"e2440591","DOI":"10.1001\/jamanetworkopen.2024.40591","article-title":"Long-term outcomes of prostate-specific membrane antigen\u2013PET imaging of recurrent prostate cancer","volume":"7","author":"Kunst","year":"2024","journal-title":"JAMA. Netw Open."},{"key":"2026082505102227000_67.8.1268.19","unstructured":"1479\u20131479r - Substitution of 68Ga-DOTA-Peptide PET\/CT Scanning in Lieu of Octreotide for Patients Undergoing Somatostatin Receptor Diagnostic Imaging under MBS Item 61369. MSAC website. https:\/\/www.msac.gov.au\/applications\/1479. Published April 2024."},{"key":"2026082505102227000_67.8.1268.20","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10585-020-10027-1","article-title":"Exploratory cost-effectiveness analysis of 68gallium-PSMA PET\/MRI-based imaging in patients with biochemical recurrence of prostate cancer","volume":"37","author":"Gordon","year":"2020","journal-title":"Clin Exp Metastasis."},{"key":"2026082505102227000_67.8.1268.21","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.euf.2019.02.013","article-title":"Modelling study with an interactive model assessing the cost-effectiveness of 68Ga prostate-specific membrane antigen positron emission tomography\/computed tomography and nano magnetic resonance imaging for the detection of pelvic lymph node metastases in patients with primary prostate cancer","volume":"6","author":"Scholte","year":"2020","journal-title":"Eur Urol Focus."},{"key":"2026082505102227000_67.8.1268.22","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.eururo.2020.11.043","article-title":"Is prostate-specific membrane antigen positron emission tomography\/computed tomography imaging cost-effective in prostate cancer: an analysis informed by the proPSMA trial","volume":"79","author":"de Feria Cardet","year":"2021","journal-title":"Eur Urol."},{"key":"2026082505102227000_67.8.1268.23","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3390\/diagnostics11020334","article-title":"Cost-effectiveness analysis of 68Ga DOTA-TATE PET\/CT, 111In-pentetreotide SPECT\/CT and CT for diagnostic workup of neuroendocrine tumors","volume":"11","author":"Froelich","year":"2021","journal-title":"Diagnostics (Basel)."},{"key":"2026082505102227000_67.8.1268.24","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1007\/s00259-021-05620-9","article-title":"Comparing the clinical performance and cost efficacy of [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 in the diagnosis of recurrent prostate cancer: a Markov chain decision analysis","volume":"49","author":"Alberts","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026082505102227000_67.8.1268.25","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s40273-022-01156-4","article-title":"Cost-effectiveness analysis of prostate-specific membrane antigen (PSMA) positron emission tomography\/computed tomography (PET\/CT) for the primary staging of prostate cancer in Australia","volume":"40","author":"Song","year":"2022","journal-title":"Pharmacoeconomics."},{"key":"2026082505102227000_67.8.1268.26","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13244-022-01265-w","article-title":"Cost-effectiveness of the implementation of [68Ga]Ga-PSMA-11 PET\/CT at initial prostate cancer staging","volume":"13","author":"van der Sar","year":"2022","journal-title":"Insights Imaging."},{"key":"2026082505102227000_67.8.1268.27","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A7901"},{"key":"2026082505102227000_67.8.1268.28","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s40273-023-01322-2","article-title":"Cost-effectiveness modeling of prostate-specific membrane antigen positron emission tomography with piflufolastat F 18 for the initial diagnosis of patients with prostate cancer in the United States","volume":"42","author":"Yee","year":"2024","journal-title":"Pharmacoeconomics."},{"key":"2026082505102227000_67.8.1268.29","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1007\/s00259-025-07190-6","article-title":"A cost-effectiveness study of PSMA-PET\/CT for the detection of clinically significant prostate cancer","volume":"52","author":"Priv\u00e9","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026082505102227000_67.8.1268.30","doi-asserted-by":"publisher","DOI":"10.3310\/hta22440"},{"key":"2026082505102227000_67.8.1268.31","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1080\/13696998.2020.1830286","article-title":"Cost-effectiveness of lutetium [177Lu] oxodotreotide versus best supportive care with octreotide in patients with midgut neuroendocrine tumors in France","volume":"23","author":"Leeuwenkamp","year":"2020","journal-title":"J Med Econ."},{"key":"2026082505102227000_67.8.1268.32","doi-asserted-by":"crossref","first-page":"43","DOI":"10.6004\/jnccn.2022.7070","article-title":"Cost-effectiveness analysis of 177Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer","volume":"21","author":"Mehrens","year":"2023","journal-title":"J Natl Compr Canc Netw."},{"key":"2026082505102227000_67.8.1268.33","unstructured":"Ohm IK Kvist BCF Lidal IB . 177Lu-PSMA-617 for treatment of metastatic castration resistant prostate cancer: a health technology assessment. Norwegian Institute of Public Health website. https:\/\/www.fhi.no\/en\/publ\/2023\/177Lu-PSMA-617-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer\/. Published 2023."},{"key":"2026082505102227000_67.8.1268.34","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.1007\/s00259-025-07317-9","article-title":"Cost-utility analysis of 177Lu-PSMA-617 radioligand therapy in second-line and third-line treatment for metastatic castration-resistant prostate cancer (mCRPC) in Germany","volume":"52","author":"Brinkmann","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026082505102227000_67.8.1268.35","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.269416"},{"key":"2026082505102227000_67.8.1268.36","unstructured":"Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto). NCBI website. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK596311\/. Published March 2023. Report No. PC0297."},{"key":"2026082505102227000_67.8.1268.37","unstructured":"Lutetium-177 Vipivotide Tetraxetan for Treating PSMA-Positive Hormone-Relapsed Metastatic Prostate Cancer after 2 or More Treatments. NICE website. https:\/\/www.nice.org.uk\/guidance\/ta930\/resources\/lutetium177-vipivotide-tetraxetan-for-treating-psmapositive-hormonerelapsed-metastatic-prostate-cancer-after-2-or-more-treatments-pdf-82615601351365. Published November 15, 2023."},{"key":"2026082505102227000_67.8.1268.38","unstructured":"Lutetium (177Lu) Oxodotreotide for Treating Unresectable or Metastatic Neuroendocrine Tumours. NICE website. https:\/\/www.nice.org.uk\/guidance\/ta539. Published August 29, 2018."},{"key":"2026082505102227000_67.8.1268.39","unstructured":"1744\u2013177 Lutetium(Nca)-DOTA-Octreotate Treatment for Advanced Neuroendocrine Tumours and Other High Somatostatin Receptor Expressing Tumours. MSAC website. https:\/\/www.msac.gov.au\/applications\/1744. Published August 2024."},{"key":"2026082505102227000_67.8.1268.40","unstructured":"Lutetium (177Lu) oxodotreotide (Lutathera): CADTH Reimbursement Review. CDA website. https:\/\/www.cda-amc.ca\/sites\/default\/files\/DRR\/2023\/PC0284-Lutathera_combined.pdf. Published January 2023."},{"key":"2026082505102227000_67.8.1268.41","unstructured":"Pan-Canadian Oncology Drug Review. Lutetium Lu 177 Dotatate (Lutathera) for Gastroenteropancreatic Nueroendocrine Tumors. CDA website. https:\/\/www.cda-amc.ca\/sites\/default\/files\/pcodr\/Reviews2019\/10142LutetiumLu177dotatateGEP-NET_fnCGR_NOREDACT_Post_01Aug2019_final.pdf. Published August 1, 2019."},{"key":"2026082505102227000_67.8.1268.42","unstructured":"1686\u2013177 Lutetium PSMA i&t for Metastatic Castrate Resistant Prostate Cancer. MSAC website. https:\/\/www.msac.gov.au\/applications\/1686-1. Published July 2022."},{"key":"2026082505102227000_67.8.1268.43","unstructured":"1686.1\u2013177 Lutetium PSMA i&t for Metastatic Castrate Resistant Prostate Cancer. MSAC website. https:\/\/www.msac.gov.au\/applications\/1686-1. Published April 2024."},{"key":"2026082505102227000_67.8.1268.44","unstructured":"1720\u201368Ga PSMA-11 PET\/CT Imaging for Patients Who Are Candidates for PSMA Targeted Therapy. MSAC website. https:\/\/www.msac.gov.au\/applications\/1720. Published April 2024."},{"key":"2026082505102227000_67.8.1268.45","doi-asserted-by":"crossref","first-page":"849","DOI":"10.7150\/thno.14744","article-title":"Towards personalized treatment of prostate cancer: PSMA I&T, a promising prostate-specific membrane antigen-targeted theranostic agent","volume":"6","author":"Chatalic","year":"2016","journal-title":"Theranostics."},{"key":"2026082505102227000_67.8.1268.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2021.10.008"},{"key":"2026082505102227000_67.8.1268.47","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/gim.2017.231","article-title":"Cost-effectiveness analysis of germ-line BRCA testing in women with breast cancer and cascade testing in family members of mutation carriers","volume":"20","author":"Tuffaha","year":"2018","journal-title":"Genet Med."},{"key":"2026082505102227000_67.8.1268.48","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00030-5"},{"key":"2026082505102227000_67.8.1268.49","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s41669-024-00537-z","article-title":"Incorporating resource constraints in health economic evaluations: overview and methodological considerations","volume":"9","author":"Thokala","year":"2025","journal-title":"Pharmacoecon Open."},{"key":"2026082505102227000_67.8.1268.50","doi-asserted-by":"crossref","unstructured":"Cookson R Griffin S Norheim OF Culyer AJ . Distributional Cost-Effectiveness Analysis: quantifying Health Equity Impacts and Trade-Offs. Oxford University Press; 2020.","DOI":"10.1093\/med\/9780198838197.001.0001"},{"key":"2026082505102227000_67.8.1268.51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.11.027"},{"key":"2026082505102227000_67.8.1268.52","unstructured":"Major radiopharmaceutical patent case exits Australia\u2019s Federal Court \u2013 Novartis\u2019 case against GenesisCare dismissed ahead of July management hearing. BioPharmaDispatch website. https:\/\/pharmadispatch.com\/news\/major-radiopharmaceutical-patent-case-exits-australias-federal-court. Published August 4, 2025."},{"key":"2026082505102227000_67.8.1268.53","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s40273-018-0633-6","article-title":"The Australian managed entry scheme: are we getting it right?","volume":"36","author":"Tuffaha","year":"2018","journal-title":"Pharmacoeconomics."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.271469","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T12:10:48Z","timestamp":1787659848000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.271469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":53,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8,3]]},"published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.2967\/jnumed.125.271469"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.271469","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]}}}